Vifor Pharma to license commercialisation rights to Pfizer’s proposed biosimilar, Retacrit™, in the field of nephrology in the US
Tuesday, 24 May 2016, ↓ directly to download
Vifor Pharma expands ESA product portfolio with rights to commercialise
Pfizer’s proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis market
Vifor Pharma, a company of the Galenica group, has further expanded its Erythropoiesis Stimulating Agent (ESA) portfolio with the licensing of commercialisation rights in the US dialysis market to Pfizer’s Retacrit™, a proposed biosimilar epoetin, in the field of nephrology.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
Friday, 23 December 2016
Friday, 9 December 2016
Monday, 28 November 2016
Thursday, 6 October 2016
Friday, 2 September 2016
Head of Corporate Communications
Head Investor Relations